Cantargia strengthens management with a Vice President Cancer Research

David Liberg has been appointed Vice President Cancer Research of Cantargia AB. Liberg has nearly twenty years of research experience within immunology and tumor biology and was graduated with a Ph.D. in immunology in 2001. Before joining Cantargia, Liberg worked at Active Biotech AB.

Cantargia strengthens the organisation with David Liberg who will take up the position as VP Cancer Research at Cantargia on December 1 2015. Liberg has for the last ten years worked within pharmaceutical industry with responsibility for early research projects and activities in tumor immunology as Project Manager Drug Development as well as head of Cell Biology and Biochemistry. Liberg has also worked with science at Imperial College in UK and at Lund University.

“We are very pleased to have succeeded with the recruitment of David Liberg. He has extensive experience of leading cancer projects in pre-clinical phases and has a well-documented knowledge within Cantargia´s research area. The recruitment of David Liberg is important and will strengthen up the development of our product candidate CAN04” says Göran Forsberg, CEO Cantargia.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 46 275 62 60
E-mail: goran.forsberg@cantargia.com

Tags: